BMS Opdivo designation a boost for UK early access scheme
This article was originally published in Scrip
The award of the UK's third "Promising Innovative Medicine" (PIM) designation, to Bristol-Myers Squibb's drug for advanced melanoma Opdivo (nivolumab), is clearly good news for the company and for patients. But it is also something of a vote of confidence in the UK's Early Access to Medicines Scheme (EAMS), amid concerns that the costs of the scheme could deter some companies from using it.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.